Literature DB >> 10557120

Should the corticosteroid to bronchodilator ratio be promoted as a quality prescribing marker?

M Frischer1, H Heatlie, S Chapman, J Norwood, J Bashford, D Millson.   

Abstract

In recent years the ratio of inhaled corticosteroid:bronchodilator (C:B) prescribing has been promoted as a quality marker for asthma treatment and cross-sectional data indicate an association with hospital admissions. If prescribing advice has been followed then it can be hypothesised that the C:B ratio will have increased and hospitalisation decreased. The West Midlands General Practice Research Database was used to monitor changes in the C:B ratio and hospital referrals for asthma between 1993 and 1996. The C:B ratio increased from 0.5 to 0.6 (P<0.001) and hospital referrals decreased from 7% to 4% per annum (P<0.001). Overall, 38% of the variation in hospital referrals was explained by the C:B ratio. This is higher than previous studies, perhaps because the study was longitudinal and the ratio assessed accurately in terms of volume rather than prescription items. When measured in defined daily doses, the C:B ratio does appear to have validity as an indicator of good prescribing in primary care. The General Practice Research Database offers an opportunity for assessing the validity of prescribing indicators before they are considered for wider use by Primary Care Groups and Health Authorities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557120     DOI: 10.1038/sj.ph.1900583

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  4 in total

1.  The predictive value of asthma medications to identify individuals with asthma--a study in German general practices.

Authors:  W Himmel; E Hummers-Pradier; H Schümann; M M Kochen
Journal:  Br J Gen Pract       Date:  2001-11       Impact factor: 5.386

2.  Factors affecting UK primary-care costs of managing patients with asthma over 5 years.

Authors:  Roben Dasgupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994.

Authors:  F Romano; G Recchia; T Staniscia; A Bonitatibus; M Villa; A Nicolosi; G De Carli; S Mannino
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

4.  Pediatric asthma mortality and hospitalization trends across Asia pacific: relationship with asthma drug utilization patterns.

Authors:  Kun Lin Chua; Shu E Soh; Stefan Ma; Bee Wah Lee
Journal:  World Allergy Organ J       Date:  2009-05       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.